Розацеа кожи: патогенез, клинические проявления, современные рекомендации по тактике ведения пациентов

Обложка


Цитировать

Полный текст

Аннотация

В обзоре обобщены и систематизированы имеющиеся международные данные по патогенезу, клиническим проявлениям и текущим рекомендациям по тактике ведения пациентов с розацеа.

Об авторах

Джим Дел Россо

Дерматологический исследовательский центр доктора Джима Дел Россо

Автор, ответственный за переписку.
Email: jqdelrosso@yahoo.com
Россия

Список литературы

  1. Tan J., Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013: 69: S27-S35.
  2. Crawford G.H., Pelle M.T., James W.D. Rosacea I: etiology, pathogenesis, and subtype classification. J Am Acad Dermatol 2004; 51: 327-341.
  3. Spoendlin J., Voegel J.J., Jick S.S., Meier C.R. A study on the epidemiology of rosacea in the UK. Br J Dermatol 2012; 167.
  4. Wilkin J., Dahl M., Detmar M. et al. Standardized classification system of rosacea: Report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol 2002; 46: 584-587.
  5. Del Rosso J.Q. Advances in understanding and managing rosacea: part 1 connecting the dots between pathophysiological mechanisms and common clinical features of rosacea with emphasis on vascular changes and facial erythema. J Clin Aesthet Dermatol 2012; 5 (3): 16-25.
  6. Del Rosso J.Q., Gallo R.L., Tanghetti E. et al. An evaluation of potential correlation between pathophysiologic mechanisms, clinical manifestations, and management of rosacea. Cutis 2013; 91 (suppl 3): 1-8.
  7. Plewig G., Kligman A.M. Rosacea. In: Plewig G., Kligman A.M., Eds, 3rd Edition, Acne and Rosacea, Springer-Verlag, Berlin, Germany, 1975: 438-445.
  8. Guzman-Sanchez D.A., Ishiuji Y., Patel T. et al. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol 2007; 57: 800-805.
  9. Rosina P., Zamperetti M., Giovannini A. et al. Videocapillaroscopic alterations in erythemato-telangiectatic rosacea. J Am Acad Dermatol 2006; 54: 100-104.
  10. Del Rosso J.Q., Thiboutot D., Gallo R. et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis 2013; 92: 234-240.
  11. Dirschka T., Tronnier H., Fölster-Holst R. Epithelial barrier function and atopic diathesis in rosacea and perioral dermatitis. Br J Dermatol 2004; 150: 1136-41.
  12. Torok H.M. Rosacea skin care. Cutis 2000; 66 (suppl 4): 14-16.
  13. Del Rosso J.Q., Thiboutot D., Gallo R. et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 5: a guide on the management of rosacea. Cutis 2014; 93: 134-38.
  14. Bamford J.T. Rosacea: current thoughts on origin. Semin Cutan Med Surg. 2001; 20: 199-206.
  15. Schwab V.D., Sulk M., Seeliger S. et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15: 53-62.
  16. Yamasaki K., Gallo R.L. The molecular pathology of rosacea. J Dermatol Sci 2009; 55: 77-81.
  17. Steinhoff M., Buddenkotte J., Aubert J. et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc 2011; 15: 2-11.
  18. Steinhoff M., Schauber J., Leyden J.J. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol 2013; 69: S15-S26.
  19. Casas C., Paul C., Lahfa M. et al. Quantification of Demodex folliculorum by PCR in rosacea and its relationship to skin innate immune activation. Exp Dermatol 2012; 21: 906-10.
  20. Forton F.M. Papulopustular rosacea, skin immunity and Demodex: pityriasis folliculorum as a missing link. J Eur Acad Dermatol Venereol 2012; 26: 19-28.
  21. McAleer M.A., Lacey N., Powell F.C. The pathophysiology of rosacea. G Ital Dermatol Venereol 2009; 144:663-671.
  22. Fleischer A.B. Jr. Inflammation in rosacea and acne: implications for patient care. J Drugs Dermatol 2011; 10: 614-620.
  23. Yamasaki K., Kanada K., Macleod D.T. et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol 2011; 131: 688-697.
  24. Meyer-Hoffert U., Schröder J.M. Epidermal proteases in the pathogenesis of rosacea. J Investig Dermatol Symp Proc 2011; 15: 16-23.
  25. Sulk M., Seeliger S., Aubert J. et al. Distribution and expression of non-neuronal transient receptor potential (TRPV) ion channels in rosacea. J Invest Dermatol 2012; 132: 1253-62.
  26. Del Rosso J.Q. Advances in understanding and managing rosacea: part 2. The central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol 2012; 5: 26-36.
  27. Yamasaki K., Di Nardo A., Bardan A. et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007; 13: 975-980.
  28. Yamasaki K., Gallo R.L. Rosacea as a disease of cathelicidins and skin innate immunity. J Invest Dermatol 2011; 15: 53-62.
  29. Layton A., Thiboutot D. Emerging therapies in rosacea. J AmAcad Dermatol 2013; 69: S57-65.
  30. Korting H.C., Schöllmann C. Tetracycline actions relevant to rosacea treatment. Skin Pharmacol Physiol 2009; 22: 287-94.
  31. Kennedy Carney C., Cantrell W., Elewski B.E. Rosacea: a review of current topical, systemic and light based therapies. G Ital Dermatol Venereol 2009; 144: 673-88.
  32. Odom R., Dahl M., Dover J. et al. Standard management options for rosacea, part 2: options according to rosacea subtype. Cutis 2009; 84: 97-104.
  33. Del Rosso J.Q. Management of facial erythema of rosacea: what is the role of topical alpha-adrenergic receptor agonist therapy? J Am Acad Dermatol 2013; 69: S44-56.
  34. Two A., Del Rosso J.Q. Kallikrein 5-mediated inflammation in rosacea: clinically relevant correlations with acute and chronic manifestations in rosacea and how individual treatments may provide therapeutic benefit. J Clin Aesthet Dermatol 2014; 7: 20-25.
  35. Tanghetti E., Del Rosso J.Q., Thiboutot D. et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis 2014; 93: 71-6.
  36. van Zuuren E.J., Kramer S.F., Carter B.R. et al. Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol 2011; 165: 760-81.
  37. Del Rosso J.Q., Thiboutot D., Gallo R. et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis 2013; 92: 277-84.
  38. Lazaridou E., Giannopoulou C., Fotiadou C. et al. The potential role of microorganisms in the development of rosacea. J Dtsch Dermatol Ges 2011; 9: 21-25.
  39. Pelle M.T., Crawford G.H., James W.D. Rosacea II: therapy. J Am Acad Dermatol 2004; 51: 499-512.
  40. Schlesinger T., Rowland C. et al. J Drugs Dermatol 2013; 12 (6): 664-667.
  41. Coda A.B., Hata T., Miller J. et al. Cathelicidin, kallikrein 5, and serine protease activity is inhibited during treatment of rosacea with azelaic acid 15% gel. J Am Acad Dermatol 2013; 69: 570-77.
  42. Del Rosso J.Q., Thiboutot D., Gallo R. et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis 2014; 93 (1): 18-28.
  43. Bakar O., Demirgay Z., Gürbüz O. Therapeutic potential of azithromycin in rosacea. Int J Dermatol 2004; 43: 151-54.
  44. Fernandez-Obregon A. Oral use of azithromycin for the treatment of acne rosacea. Arch Dermatol 2004; 140: 489-90.
  45. Kanada K.N., Nakatsuji T., Gallo R.L. Doxycycline indirectly inhibits proteolytic activation of tryptic kallikrein-related peptidases and activation of cathelicidin. J Invest Dermatol 2012; 132: 1435-42.
  46. Sapadin A.N., Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol 2006; 54: 258-65.
  47. Del Rosso J.Q. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis 2006; 78: 97-100.
  48. Del Rosso J.Q. Anti-inflammatory dose doxycycline in the treatment of rosacea. J Drugs Dermatol 2009; 8: 664-68.
  49. Bikowski J.B. Subantimicrobial dose doxycycline for acne and rosacea. Skinmed 2003; 2: 234-45.
  50. Del Rosso J.Q., Webster G.W., Jackson M. et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol 2007; 56: 791-802.
  51. Preshaw P.M., Novak M.J., Mellonig J. et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol. 2008; 79: 440-52.
  52. Skidmore R., Kovach R., Walker C. et al. Effects of subantimicrobial-dose doxycycline in the treatment of moderate acne. Arch Dermatol 2003; 139: 459-64.
  53. Park H., Del Rosso J.Q. Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol 2011; 4: 54-61.
  54. Hieble J.P. Subclassification and nomenclature of alpha- and beta-adrenoreceptors. Curr Top Med Chem 2007; 7: 129-34.
  55. Johnson J.M., Kellogg D.L. Local thermal control of human cutaneous circulation. J Appl Physiol 2010; 109: 1229-38.
  56. Kim J.H., Oh Y.S., Ji J.H. et al. Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline. J Dermatol 2011; 38: 510-13.
  57. Fowler J., Jarratt M., Moore A. et al. Once-daily topical brimonidine tartrate gel 0.5% is a novel treatment of moderate to severe facial erythema of rosacea: results of two multicenter, randomized and vehicle-controlled studies. Br J Dermatol 2012 Mar; 166 (3): 633-41.
  58. Shanler S.D., Ondo A.L. Successful treatment of erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor antagonist, oxymetazoline. Arch Dermatol 2007; 143: 1369-71.
  59. Benkali K., Leoni M., Rony F. et al. Br J Dermatol. 2014 Feb 7. doi: 10.1111/bjd.12881. [Epub ahead of print].
  60. Fowler J. Jr., Jackson M., Moore A. et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol 2013; 12: 650-56.
  61. Moore A., Kempers S., Murakawa G. et al. Longterm safety and efficacy of once-daily topical brimonidine tartrate gel 0.5% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol 2014; 13: 56-61.
  62. Ilkovitch D., Pomerantz R.G. Brimonidine effective but may lead to significant rebound erythema. J Am Acad Dermatol 2014; 70 (5): e109-10. doi: 10.1016/j.jaad.2014.01.853.
  63. Routt E.T., Levitt J.O. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33%. J Am Acad Dermatol 2014; 70: 37-8.
  64. Dourmishev A.L., Dourmishev L.A., Schwartz R.A. Ivermectin: pharmacology and application in dermatology. International Journal of Dermatology. 2005; 44: 981-88.
  65. Forstinger C., Kittler H., Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol 1999; 41: 775-77.
  66. Salem D.A., El-Shazly A., Nabih N. et al. Evaluation of the efficacy of oral ivermectin in comparison with ivermectin-metronidazole combined therapy in the treatment of ocular and skin lesions of Demodex folliculorum. Int J Infect Dis 2013; 17: 343-47.
  67. Stein Gold L., Kircik L., Fowler J. et al. Efficacy and safety of ivermectin 1% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol 2014; 13 (3): 316-23.
  68. Stein Gold L., Kircik L., Fowler J. et al. Longtern safety of ivermectin 1% cream vs azelaic acid 15% gel in treating inflammatory lesions of rosacea: results of two 40-week controlled, investigator-blinded trials. J Drugs Dermatol 2014; 13 (11): 1380-1388.
  69. Taieb A., Ortonne J.P., Ruzicka T. et al. Superiority of ivermectin 1% cream over metronidazole 0.75% cream in treating inflammatory lesions of rosacea: a randomized, investigator-blinded trial. Br J Dermatol 2015; 172 (4): 1103-1110.
  70. Bhatia N.D., Del Rosso J.Q. Optimal management of papulopustular rosacea: rationale for combination therapy. J Drugs Dermatol 2012; 11: 838-844.

Дополнительные файлы

Доп. файлы
Действие
1. JATS XML
Скачать

© Дел Россо Д., 2016

Creative Commons License
Эта статья доступна по лицензии Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77 - 60448 от 30.12.2014.


Данный сайт использует cookie-файлы

Продолжая использовать наш сайт, вы даете согласие на обработку файлов cookie, которые обеспечивают правильную работу сайта.

О куки-файлах